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An important factor in the universal failure in phase III trials in mild to moderate Alzheimer’s disease in the past
decade is the lack of phase II clinical data prior to entering phase III, with common reliance on biomarker results
alone. Conduction of two learn-confirm cycles according to the Sheiner model would allow go/no-go decision
making to include reliable clinical efficacy data prior to conducting phase III and would likely bring the rate of late
stage failure more into line with that of other neurological indications. In studies in earlier disease stages, combined
phase IIB/III adaptive approaches merit consideration in view of the long timelines of each study, though advantages
and disadvantages of this approach versus the classical development pathway still need careful assessment.Introduction
Not a single compound has successfully completed
phase III in Alzheimer’s disease (AD) over the past
11 years [1, 2]. This success rate in phase III is far worse
than that for the average of all neurological conditions
combined, estimated to be approximately 50 % in a re-
cent review [3]. Apart from the general difficulty of
translating preclinical findings to clinical results in the
AD area, there may be many reasons behind this extraor-
dinarily high failure rate, including design issues such as
potential under- or over-dosing [4, 5] and ‘regression to
the mean’ after proceeding to phase III on the basis of ran-
dom high phase II results [6]. More importantly, it seems
that there has been a recent trend to enter phase III with-
out adequate phase II data on clinical efficacy [2], the deci-
sion being based instead on positive effects on biomarkers.
A now classical model of development of new medi-
cines (see above) entails two ‘learn-confirm’ cycles [7], as
shown in Fig. 1.
According to this model, in the first cycle, initial learning
occurs in phase I tests of safety and pharmacodynamics
and pharmacokinetics. This is followed by confirmation of
the safety and pharmacodynamics/target engagement as
well as, if feasible, initial evidence of clinical efficacy in
phase IIA studies in relatively small groups of patients.
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second learn-confirm cycle, with final confirmation of
efficacy and safety in larger numbers of patients in phase
III studies. Inevitably the model is oversimplified, with
important learning occurring throughout development.
However, the basic concept remains valuable.
The duration of this full two-cycle approach may appear
daunting in the case of disease-modifying studies, and ef-
forts are often made to short-cut this by combining
phases. A combined phase I/IIA study in patients could,
for example, bring sufficient data on safety, phar-
macokinetics and pharmacodynamics. Nevertheless, this is
not sufficient as a database to commence phase III as
preliminary information about clinical effect size and
dose–response in a phase IIB study should first be col-
lected to enable proper planning of these definitive studies.
Few recent AD programs have followed this model,
with sponsors tending to commence a full phase III
program after seeing evidence of target engagement
biochemically in smaller phase II studies. The imperfect
link between results on biomarkers and clinical effects
observed to date makes this a high risk approach, which,
if it continues to be followed by phase III failure, may
lead to reduced attractiveness of the area as one for
investment in the future.
In contrast, the two-cycle model was followed for
currently approved agents for treating AD. For example,
donepezil showed clinical efficacy in phase II [8] before
conduction of phase III studies [9, 10], which were also
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Fig. 1 Learn-confirm model of medicines development [7, 18]. Figure reproduced with permission from [18]
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anti-amyloid phase III study has been preceded by a
positive phase II proof of concept study. Instead the
decision to move to phase III has at times been made
based on positive data on effects on biomarkers rather
than clinical endpoints: an example here is that of sola-
nezumab [2], where after entering phase III studies
based on biomarker and safety data in phase II, the first
phase III results did not reach statistical significance
(though the study led to design of the further ongoing
phase III study in mild patients). Moving to phase III
based on positive clinical results in subgroups but not
the overall analysis in phase II also carries significant
risk as exemplified by the failure in phase III of taren-
flurbil in mild AD, a subgroup with apparently positive
results in phase II [11]. The motivation to skip phase IIB
studies prior to entry into phase III for the newer
disease-modifying agents may be prompted partly by the
long duration of such studies and the drive for commer-
cial organisations to enter the market as early as pos-
sible. Another factor behind the leap into phase III may
be concern over issues around statistical power in phase
II. Of course, the sample size estimation is dependent on
both the magnitude of the response and associated vari-
ability - which may be conveniently combined into an
‘effect size’ consisting of the mean difference between ac-
tive and control groups divided by the standard deviation
of the difference. Continuous development failures in the
AD field have led to more cautious anticipated effect
sizes - with consequently larger predicted sample sizes
needed to show them.
Effect sizes of 0.4 or even less are now commonly pre-
dicted in trials of new agents for treating AD, even
though larger effect sizes (0.6 or more) are commonly
required in other therapeutic areas. The high variability
in rates of decline on placebo between studies [12] adds
to the tendency to be conservative in sample size
estimation.
Concretely, in a mild to moderately demented popula-
tion, use of a reliable cognitive instrument to demonstrate
a modest effect size of 0.4 would require at least 100 sub-
jects per group (two group t-test with 80 % power and
0.05 significance level (two tailed)). Adding to this number
additional patients to compensate for a reasonably likelydropout rate (20 %), and assuming multiple dose groups
(low, medium, high) with a placebo control comparator, re-
sults in a phase IIB study with approximately 500 subjects.
For agents with smaller effect sizes such studies will
inevitably be underpowered to show significance at the
5 % level. However, simply demonstrating statistically
significant P values is of lesser importance in this learn-
ing phase of development: instead, the goal should be to
quantify the magnitude of treatment effect on clinical
endpoints and to estimate the precision of the estimate
(particularly with respect to the expected minimum ef-
fect size from the lower confidence boundary) not only
across a range of endpoints and instruments but also
across the different dose groups and times of assessment.
Dose-dependency and consistency of effects at different
time-points and across different scales and subgroups can
provide support for the existence of a real drug effect.
Recent results with monoclonal antibodies directed
against beta-amyloid have indicated that efficacy may be
greater when such agents are applied early in the disease
process. In particular, encouraging results on clinical
endpoints have been obtained especially in mild rather
than moderate AD patients with solanezumab in phase
III studies [13], with the same trends to better response
in milder patients observed in a dose-dependent manner
in a 433-patient phase IIB study of crenezumab [14].
With smaller placebo declines in mild AD and in even
earlier disease stages such as prodromal and preclinical
AD, low power in phase II studies may become an in-
creasingly critical issue for modestly effective compounds.
Regulatory aspects of developing drugs at these early dis-
ease stages have been discussed in a recent US Food and
Drug Administration guidance document [15]. Deve-
lopment in early AD may require new approaches. For
example, involvement of patients in larger phase I studies
may allow initial learning about clinical efficacy as in the
recently reported positive preliminary results with aduca-
numab [16]. Such studies may effectively then become
phase I/IIA studies as they take on some of the character
of phase II studies. Likewise, it is possible to try to com-
bine learning with confirming by using adaptive design or
Bayesian approaches in a phase IIB study (which may then
become a phase IIB/III study) [17] to allow discontinu-
ation of inactive doses and adjust the sample size to
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the same time controlling the overall experiment-wise
type I error rate. Such a study could potentially then act
as a pivotal study - though at the expense of greatly in-
creased complexity and higher potential cost associated
with the larger number of patients which may eventually
be included. A positive outcome at interim analysis could
also trigger the start of a second phase III study. While in-
tellectually appealing, the protracted timelines of such
studies in disease-modifying trials, the inability to disclose
and publicise phase II findings as well as the potential is-
sues associated with introduction of bias at the time of in-
terim analysis means that such approaches must be used
only after careful assessment of the risks and benefits as
well as discussions with regulatory authorities.
Conclusion
During the last 10 to 15 years of clinical trials in AD we
have seen an increasing tendency to enter phase III
without conducting or carefully analysing adequately
sized phase II studies. We recommend that phase II
studies should be designed and conducted with both
clinical endpoints to estimate clinical effect size, and
biomarkers to establish target engagement prior to start-
ing phase III in mild or moderately demented patients.
In studies in earlier disease stages, combined phase IIB/
III adaptive approaches merit consideration in view of
the long timelines of each study, though advantages and
disadvantages of this approach versus the classical devel-
opment pathway still need careful assessment. Only by
‘looking before leaping’, can we bring down the rate of
phase III failures, which have become an all too com-
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